Startups
æå·å¾·éçç©ç§æè¡ä»½æéå
¬å¸ï¼ç®ç§°å¾·éç§æï¼æ¸¯è¡ä»£ç 02526.HKï¼æ¯AIå»å¦å½±åé¢åä¸å¸ä¼ä¸ï¼æä¾AIæè²ä½æ ¸ååæç³»ç»ãå»å¦å½±å大模åiMedImageãiMed MaaSå¹³å°åç»èéä¼ å®éªå®¤èªå¨å产åä¸è§£å³æ¹æ¡ã
Overview
Location
China
Employees
51-200
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 30, 2026 | Diagens Annual Results: 100B-Parameter Model Reshapes Medical AI Landscape; Licensing Revenue Becomes Primary Growth Engine | HONG KONG and HANGZHOU, China, April 30, 2026 /PRNewswire/ -- Hangzhou Diagens Biotech Co., Ltd. (HKEX: 2526, "Diagens"), a pioneer in medical imaging foundation models, today announced its first annual results since its listing. ... |
| Mar 16, 2026 | Diagens nears IPO with medical imaging AI, foundation model | Diagens Biotechnology has passed a listing hearing with the Hong Kong Stock Exchange and disclosed its post-hearing prospectus on March 15, with Huatai International serving as the sole sponsor. The move puts the Hangzhou-based firm on trac... |
| Apr 15, 2023 | Introducing the MetaSight® G200: A Revolutionary Third-Generation Chromosomal Karyotyping System Transforming Global Chromosomal Analysis | CHANGSHA, China, April 15, 2023 /PRNewswire/ -- The MetaSight® G200 is a groundbreaking karyotyping system based on high-resolution microscopy technology, capable of accurately detecting chromosomal abnormalities in humans. This innovative ... |
| Apr 15, 2023 | Introducing the MetaSight® G200: A Revolutionary Third-Generation Chromosomal Karyotyping System Transforming Global Chromosomal Analysis | CHANGSHA, China, April 15, 2023 /PRNewswire/ -- The MetaSight® G200 is a groundbreaking karyotyping system based on high-resolution microscopy technology, capable of accurately detecting chromosomal abnormalities in humans. This innovative ... |
| DIAGENS | “Hangzhou Dezhao Biotechnology Co., Ltd., established in 2014, is located in Hangzhou, Zhejiang Province, is a professional team of high-tech enterprises, with independent intellectual property rights of pre-production innovation instrument... | |
| DIAGENS | “Hangzhou Dezhao Biological Technology Co., Ltd” |
Reviews 0
FAQ about DIAGENS
What has the press written about DIAGENS?
Parsers VC has collected 7 articles mentioning DIAGENS, among them “Diagens Annual Results: 100B-Parameter Model Reshapes Medical AI Landscape; Licensing Revenue Becomes Primary Growth Engine” (Apr 30, 2026) and “Diagens nears IPO with medical imaging AI, foundation model” (Mar 16, 2026).
Is DIAGENS still active?
Yes, DIAGENS is active; its latest activity on Parsers VC dates from Jul 10, 2026.